Oramed Pharmaceuticals (NASDAQCM:ORMP) is developing proprietary Protein Oral Delivery (POD) technology for the delivery of drugs presently administered by way of injection. Through its patented flagship product, an orally ingestible insulin capsule currently approaching a Phase 2b multi-center trial under the USFDA, the Company is seeking to revolutionize the treatment of diabetes.

In the News

May Issue - Diabetes Forecast: What’s Next for Insulin: No Needles? Read here.
For more on Oramed in the news, click here.
Press Releases


August 19, 2014

Oramed Granted Patent in Spain for Oral Administration of Insulin

...read more>>



August 7, 2014

Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes

...read more>>



June 23, 2014

Oramed Pharmaceuticals to Present at the BIO International Convention in San Diego

...read more>>


June 10, 2014

Oramed Pharmaceuticals to Present at the American Diabetes Association 74th Scientific Sessions on June 13 - 17, 2014 in San Francisco

...read more>>



May 29, 2014

Oramed Pharmaceuticals Added to the Morgan Stanley Capital International (MSCI) MicroCap Index

...read more>>



May 27, 2014

Oramed to Present at Jefferies Global Healthcare Conference on June 2 in New York City

...read more>>



May 19, 2014

Oramed Pharmaceuticals to Present at the IATI Israel Innovation Conference in Tel Aviv

...read more>>






Press Center | Terms & Conditions | Privacy Statement Design and programming by BIGDESIGN Creative Agency | All rights reserved © 2009 Oramed